pocketful logo
Eiko Lifesciences Ltd logo

Eiko Lifesciences Ltd

NSE: BSE: 540204

53.04

(2.16%)

Sat, 21 Mar 2026, 03:53 am

Eiko Lifesciences Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    75.60

  • Net Profit

    2.32

  • P/B

    1.27

  • Sector P/E

    38.47

  • P/E

    31.15

  • EV/EBITDA

    15.88

  • Debt/Equity (Industry)

    0.40

  • Interest Cover (Industry)

    3.18

  • ROCE (Industry)

    6.27

  • RONW (Industry)

    4.62

  • ROE

    3.61

  • ROCE

    4.84

  • Debt/Equity

    0.05

  • EPS (TTM)

    2.78

  • Dividend Yield

    0

  • Book Value

    43.37

  • Interest Cover

    16.97

Analysis

all

thumbs up icon

Pros

  • Debt is covered by short term assets, assets are 2.9x debt.
  • Narendra Investments (Delhi)'s cash and other short term assets cover its long term commitments.
  • The tenure for the Narendra Investments (Delhi) board of directors is about average.
  • BSE:540204 is up 92.7% outperforming the Capital Markets industry which returned 8.7% over the past month.
  • BSE:540204 is up 92.7% outperforming the market in India which returned 8% over the past month.
thumbs up icon

Cons

  • Unable to calculate sustainability of dividends as Narendra Investments (Delhi) has not reported any payouts.
  • Unable to evaluate Narendra Investments (Delhi)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Narendra Investments (Delhi)'s dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Narendra Investments (Delhi)'s short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Debt is not well covered by operating cash flow (11.6%, less than 20% of total debt).

Read More

Financials

No Result Found

Read More

Ratios

No Result Found

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters37.1737.1736.7436.2331.27
FII00000
DII00000
Public62.8362.8363.2663.7768.73
Government00000

Read More

Technical Analysis

RSI

50.13

MACD

0.31

50 DMA

52.07

200 DMA

52.92

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic63.4557.6154.5351.7748.6945.9340.09
Fibonacci57.6155.3854.0051.7749.5448.1645.93
Camarilla53.0752.5352.0051.7750.9250.3949.85

Pivots Level: Classic

R3

+11.68

63.45

R2

+5.84

57.61

R1

+2.77

54.53

51.77
51.77
Pivot Point
LTP: 52.40

S1

-3.07

48.69

S2

-5.84

45.93

S3

-11.68

40.09

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    52.78

  • 20-EMA

    52.47

  • 30-EMA

    52.35

  • 50-EMA

    52.32

  • 100-EMA

    52.49

  • 200-EMA

    53.02

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 Jan 2026board-meetingsQuarterly Results
11 Dec 2025egm
31 Oct 2025board-meetingsQuarterly Results, Half Yearly Results
29 Jul 2025agm
09 Sept 2024agm
30 Aug 2023agm
30 Jun 2023rights2:3 Rights Issue of Equity Shares07 Jul 2023
07 Jun 2023rightsRight Issue of Equity Shares07 Jul 2023
02 Jun 2022agm
25 Aug 2021agm

Read More

Peer Comparison

No Result Found

Eiko Lifesciences Ltd logo

Eiko Lifesciences Ltd

Navin Fluorine International Ltd logo

Navin Fluorine International Ltd

Linde India Ltd logo

Linde India Ltd

SRF Ltd logo

SRF Ltd

Pidilite Industries Ltd logo

Pidilite Industries Ltd

Gujarat Fluorochemicals Ltd logo

Gujarat Fluorochemicals Ltd

Read More

Eiko Lifesciences Ltd About

Eiko Lifesciences manufacturing processes by adopting the best available technology, which is environmentally sustainable and safe to operate.

Industry

Chemicals

Founded

1977

Headquarters

CEO

Laxmikant Kabra

Employees

Contact

Website icon

Website

http://www.eikolifesciences.com

Email icon

Email

investor.relations@eikolifesciences.com

Phone icon

Phone

91-22-25390009/25438095

Location icon

Location

1st Matru Chhaya Ground Floor, M Karve Road Naupada, Thane, Maharashtra, 400602

Read More

Eiko Lifesciences Ltd Company History

YearHistory
1977
  • Narendra Investments (Delhi) Limited was incorporated.
2016
  • The equity shares of Narendra Investments (Delhi) Ltd were listed.
2021
  • The company name was changed to Eiko Lifesciences Ltd. from Narendra Investments (Delhi) Ltd.
2023
  • The company issued rights shares of Rs. 10 in the ratio of 2:3 at a premium of Rs. 35 per share.
2024
  • The Company entered into a definitive business agreement with Vivacious Pharmatex Private Limited.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
SIDDHANT LAXMIKANT KABRABuy7100049.0625 Jun 2025
SIDDHANT LAXMIKANT KABRABuy13000051.6527 Mar 2025
2B BLACK BIO LLPSell13700051.6727 Mar 2025
SIDDHANT LAXMIKANT KABRABuy7300050.7318 Feb 2025
2B BLACK BIO LLPSell6819950.718 Feb 2025
JOYANTAKUMARJANABuy8335067.4911 Jul 2024
ARITRO ASHISH ROYSell15255066.8511 Jul 2024
SAURABHTRIPATHIBuy8000059.7710 Jul 2024
ARITRO ASHISH ROYSell1074155105 Jul 2024
ARITRO ASHISH ROYSell7610049.0306 Jun 2024

Read More

Eiko Lifesciences Ltd News

Eiko Lifesciences Allots 6.25 Lakh Shares & Warrants

Eiko Lifesciences completes preferential allotment of 6,25,000 equity shares worth Rs. 3,43,75,000 and 29,50,000 warrants worth Rs. 4,05,62,500 to promoters and investors at Rs. 55 per share.

24 Feb 2026

co actions results

Eiko LifeSciences Shareholders Approve Warrant Issuance

Eiko LifeSciences Limited shareholders approved two special resolutions for issuance of 33,00,000 warrants and 6,75,000 equity shares on preferential basis during extraordinary general meeting held on January 7, 2026.

09 Jan 2026

co actions results

Eiko LifeSciences Promoter Entity Faces SEBI Penalty

SEBI imposed ₹1.00 lakh penalty on Eiko LifeSciences' promoter group entity Lenus Finvest for alleged non-compliance with SAST regulations during November 2019 to June 2021. Company confirms no financial impact.

05 Jan 2026

stocks

Eiko Life Sciences EGM for ₹21.86 cr fundraise

Eiko Life Sciences to hold EGM on January 7, 2026, seeking approval for preferential issue of 33 lakh warrants at ₹55 each and 6.75 lakh equity shares, raising ₹21.86 crores for strategic acquisition of SSM Formulations.

12 Dec 2025

co actions results

Eiko Lifesciences Acquires 51% Stake in SSM Formulations

Eiko Lifesciences board approves acquisition of 51% equity in WHO-GMP accredited SSM Formulations for ₹18 crores, marking transformation into fully integrated pharmaceutical player with global footprint.

11 Dec 2025

co actions results

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800